Sanofi Genzyme logo
IMPORTANT SAFETY INFORMATION: Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been reported in less than 1% of patients... View more

What is Cerezyme?

Cerezyme is the ONLY ERT (enzyme replacement therapy) that hasshown long-term efficacy and safety in multiple studies over 10 yearsand has been prescribed for over 20 years.

View Indications and Usage

What is Cerezyme?

People with Gaucher disease type 1 may not have enough of an enzyme called acid beta-glucocerebrosidase (pronounced gloo-ko-ser-e-bro-sydaze) that breaks down a fatty substance called glucosylceramide (gloo-ko-sil-sara-mide), or GL-1. This causes a build-up of GL-1 in key organs such as the spleen and liver, as well as in the bones, leading to the signs and symptoms of Gaucher disease.

Cerezyme is a modified form of the enzyme glucocerebrosidase, and it works to reduce the build-up of GL-1 in the body.

Cerezyme has been used since 1994 all around the world

Cerezyme has been used since 1994 in thousands of patients with Gaucher disease type 1 around the world

How Cerezyme works

Cerezyme is designed to reduce the build-up of GL-1 in people who do not have enough of the natural enzyme to keep up with their bodies’ production.

Cerezyme acts like glucocerebrosidase (the body’s natural enzyme), breaking down GL-1 into its more basic elements, glucose and ceramide, that can be naturally removed from the body.

Cerezyme may help

Cerezyme may help

The most studied ERT in children and adults with Gaucher disease type 1

See results
Learn the causes of Gaucher disease

Understanding Gaucher disease

Learn the causes and symptoms of Gaucher disease

Get facts

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  • anemia (low red blood cell count)
  • thrombocytopenia (low blood platelet count)
  • bone disease
  • hepatomegaly or splenomegaly (enlarged liver or spleen)

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been reported in less than 1% of patients. Symptoms suggestive of allergic reaction happened in approximately 7% of patients, and include itching, flushing, hives, swelling, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure. If you have had an allergic reaction to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.

High blood pressure in the arteries of the lungs (pulmonary hypertension) and pneumonia have been observed in less than 1% of patients during treatment with Cerezyme. These are also known complications of Gaucher disease regardless of treatment. If you experience symptoms such as shortness of breath or chest pain, with or without fever, contact your doctor.

Approximately 14% of patients have experienced side effects related to treatment with Cerezyme. Some of these reactions occur at the site of injection such as discomfort, itching, burning, swelling or uninfected abscess. Other side effects, each of which was reported by less than 2% of patients, include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Temporary swelling in the legs has also been observed with drugs like Cerezyme.

Please see Full Prescribing Information (PDF).